Brief: Unity Biotechnology Completes Enrollment In Phase 2 Envision Study Of UBX1325 In Wet Age-Related Macular Degeneration
19/09/2022 13:23
Sept 19 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY COMPLETES ENROLLMENT IN PHASE 2
ENVISION
STUDY OF UBX1325 IN WET AGE-RELATED MACULAR DEGENERATION
* UNITY BIOTECHNOLOGY - ENROLLMENT OF 51 PATIENTS EXCEEDS
TARGET
BY ABOUT 10% DUE TO HIGH INTEREST IN THE STUDY
* UNITY BIOTECHNOLOGY - 16-WEEK DATA ANTICIPATED IN Q1 2023
AND
24-WEEK DATA ANTICIPATED IN Q2 2023
Source text for Eikon: ID:nGNX5XF6Cy
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force